Advance Search
PAN Dong, PU Lijun, WANG Wei, WANG Rui, LUO Yong. Comparative study of sacubitril/valsartan andperindopril in improving ventricular remodeling in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 93-97. DOI: 10.7619/jcmp.20201469
Citation: PAN Dong, PU Lijun, WANG Wei, WANG Rui, LUO Yong. Comparative study of sacubitril/valsartan andperindopril in improving ventricular remodeling in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 93-97. DOI: 10.7619/jcmp.20201469
shu

Comparative study of sacubitril/valsartan andperindopril in improving ventricular remodeling in patients with chronic heart failure

  • 1.

    Department of Cardiology, Bazhong City Central Hospital of Sichuan Province, Bazhong, Sichuan, 636000

  • 2.

    Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000

  • 3.

    Department of Cardiology, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000

More Information
  • Received Date: November 16, 2020
  • Available Online: April 20, 2021
  • Published Date: April 14, 2021
    Graphical Abstract
    • Abstract
  •   Objective  To investigate the efficacy of sacubitril/valsartan and perindopril in improving ventricular remodeling in patients with chronic heart failure.
      Methods  A total of 115 heart failure patients were divided into group A (n=84) and group B (n=71). The types of heart failure in the two groups were heart failure with reduced ejection fraction(HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and heart failure preserved ejection fraction (HFpEF). On the basis of conventional medication, sacubitril/valsartan was added to the group A, and perindopril was added to the group B. Echocardiographic related indexes of two groups before and after treatment were analyzed and compared.
      Results  The values of left ventricular ejection fraction (LVEF) in the two groups were significantly higher than those before treatment (P < 0.05). After 6 months of treatment, the values of LVEF in patients with HFrEF and HfmrEF types of the group A were significantly higher than those in the group B (P < 0.05). Left ventricular end diastolic dimension (LVEDd), left atrial diameter (LA) and left ventricular mass index (LVMI) in the two groups were significantly decreased than those before treatment (P < 0.05).
      Conclusion  Both sacubitril/valsartan and perindopril can improve left ventricular remodeling in patients with different types of chronic heart failure.
    • FullText(HTML)
    • References (15)
  • [1]
    PONIKOWSKI P, ANKER S D, ALHABIB K F, et al. Heart failure: preventing disease and death worldwide[J]. ESC Heart Fail, 2014, 1(1): 4-25. doi: 10.1002/ehf2.12005
    [2]
    黄峻. 中国心力衰竭流行病学特点和防治策略[J]. 中华心脏与心律电子杂志, 2015, 3(2): 2-3. https://www.cnki.com.cn/Article/CJFDTOTAL-XZXL201502003.htm
    [3]
    SENNI M, MCMURRAY J J, WACHTER R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J]. Eur J Heart Fail, 2016, 18(9): 1193-1202. doi: 10.1002/ejhf.548
    [4]
    ALMUFLEH A, MARBACH J, CHIH S, et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients[J]. Am J Cardiovasc Dis, 2017, 7(6): 108-113. http://www.ncbi.nlm.nih.gov/pubmed/29348971
    [5]
    FERRARI R, Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study[J]. Arch Intern Med, 2006, 166(6): 659-666. doi: 10.1001/archinte.166.6.659
    [6]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [7]
    中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(5): 421-434. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB201805001.htm
    [8]
    SALAH K, STIENEN S, PINTO Y M, et al. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction[J]. Heart Br Cardiac Soc, 2019, 105(15): 1182-1189. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_bmj-open-access_thesis/040004828823.html
    [9]
    MAEJIMA Y, OKADA H, HARAGUCHI G, et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma[J]. Lab Invest, 2011, 91(6): 932-944. doi: 10.1038/labinvest.2011.45
    [10]
    FU S, PING P, WANG F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng, 2018, 12: 2. doi: 10.1186/s13036-017-0093-0
    [11]
    SUEMATSU Y, JING W, NUNES A, et al. LCZ696 (sacubitril/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease[J]. J Card Fail, 2018, 24(4): 266-275. doi: 10.1016/j.cardfail.2017.12.010
    [12]
    PARFREY P S, LAUVE M, LATREMOUILLE-VIAU D, et al. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis[J]. Clin J Am Soc Nephrol, 2009, 4(4): 755-762. doi: 10.2215/CJN.02730608
    [13]
    SCHMIEDER R E, WAGNER F, MAYR M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study[J]. Eur Heart J, 2017, 38(44): 3308-3317. doi: 10.1093/eurheartj/ehx525
    [14]
    SOLOMON S D, ZILE M, PIESKE B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851): 1387-1395. doi: 10.1016/S0140-6736(12)61227-6
    [15]
    JANUZZI J L JR, PRESCOTT M F, BUTLER J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA, 2019, 322(11): 1-11. http://d.wanfangdata.com.cn/periodical/ChlQZXJpb2RpY2FsRW5nTmV3UzIwMjEwMzAyEiA2NzJkZmUyMjdhZmJiOGQxZjcyZDVlZmVlYzYyMDQzNhoINXM0dHVqMmM%3D
    • Related Articles

  • Related Articles

    [1]YU Fulin, HUANG Jiangbo, NING Yangshan. Correlations of serum phosphoglycerate mutase family member 5 and YT521-B homology N6-methyladenosine RNA binding protein 2 levels with ventricular remodeling and prognosis in patients with heart failure with preserved ejection fraction[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 64-69. DOI: 10.7619/jcmp.20244630
    [2]Gulimila ·ABUDUKAHA, LI Yatan, YANG Fan. Regulation of atorvastatin on the Hippo-YAP signaling pathway in rats with chronic heart failure and its impact on ventricular remodeling[J]. Journal of Clinical Medicine in Practice, 2024, 28(22): 55-61. DOI: 10.7619/jcmp.20241911
    [3]YANG Rui, YU Junmin, ZHANG Xiaobo, LI Dahe, ZHAO Yuanyuan, CHEN Hongye. Research progress on molecular mechanism related to ventricular remodeling in elderly patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 139-143. DOI: 10.7619/jcmp.20231891
    [4]YAO Dan, ZHENG Ju, PANG Chong, WU Yanming, YOU Hua. Effect of sacubitril/valsartan on echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 81-84, 88. DOI: 10.7619/jcmp.20210125
    [5]QIU Qingyan, DAI Min, MOU Ying, YU Hui. Effect of metoprolol combined with trimetazidine on serum angiotensin Ⅱ and vascular endothelial function in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 99-102, 106. DOI: 10.7619/jcmp.20200912
    [6]WANG Juping, YANG Weilun, SHI Le. Pharmacological mechanism and research progress of traditional Chinese medicine in the treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 125-128. DOI: 10.7619/jcmp.202012035
    [7]TANG Yong, LU Yong. Clinical effect of Qili Qiangxin Capsule combined with nicorandil in treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 35-38. DOI: 10.7619/jcmp.202012010
    [8]ZHANG Liwei. Correlations between serum uric acid, N-terminal pro-B-type natriuretic peptide, vasostatin-2 and left ventricular ejection fraction in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 29-31. DOI: 10.7619/jcmp.202012008
    [9]TANG Yuanyuan, HOU Xiaofeng, WANG Yao, ZOU Jiangang. Correlation between serum N-terminal pro-brain natriuretic peptide, serum cystatin C and left ventricular remodeling in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2015, (24): 59-62. DOI: 10.7619/jcmp.201524018
    [10]HU Huan, WANG Xiang. Correlation between plasma brain natriuretic peptide and left ventricular remodeling[J]. Journal of Clinical Medicine in Practice, 2013, (21): 19-23. DOI: 10.7619/jcmp.201321006

Catalog

    Get Citation
    PDF
    XML
    Article views (384) PDF downloads (40) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return